2019 American Transplant Congress
Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. We…2018 American Transplant Congress
Building a Third-Party VST Bank from Scratch- The Cincinnati Experience
BackgroundViral infections remain a challenge to treat and significantly contribute to morbidity and mortality. Virus specific T cells (VSTs) have shown clinical efficacy, with minimal…2018 American Transplant Congress
Prospective, Multi-Center Observational Study of Cell-Mediated Immunity for Cytomegalovirus Infection in Kidney Transplant Recipients
Background:T-cell-mediated immunity (CMI) is crucial for the control of CMV infection post-transplant. We evaluated a novel EliSpot assay to determine whether CMI results could predict…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Direct-Acting Antiviral Therapy Immune-Mediated Graft Dysfunction in Liver Transplant Recipients with Hepatitis C
Background and Aims:Interferon (IFN) treatment of hepatitis C virus (HCV) infection after liver transplantation (LT) can result in severe immune-mediated graft dysfunction (IGD). The occurrence…2018 American Transplant Congress
Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment
Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…2018 American Transplant Congress
An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation
Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…2018 American Transplant Congress
Brincidofovir Was Used to Successfully Treat Adenovirus Infections in Solid Organ Transplant Recipients and Other Immunocompromised Patients
Background: Adenovirus (AdV) infections cause significant morbidity and mortality in immunocompromised patients. Brincidofovir (BCV) is an investigational antiviral drug with high in vitro potency against…2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…2018 American Transplant Congress
Early Adjunctive Treatment with Human Cytomegaly Virus (CMV) Immunoglobulin Increased CMV-Free Survival after Heart Transplantation
Purpose: There is still an ongoing discussion whether a prophylactic or a preemptive therapy against cytomegalovirus (CMV) is superior to reduce the incidence of CMV…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 14
- Next Page »